Product Description

KDM5C Monoclonal Antibody

Sizes: 50μl, 100μl

Catalogue Numbers: MB66471-50, MB66471-100

Lead times: 1-2 weeks, if manufacturer has product in stock

Manufacturer/Ship Location: China

Background: The methylation state of lysine residues in histone proteins is a major determinant for formation of active and inactive regions of the genome and is crucial for proper programming of the genome during development. Jumonji C (JmjC) domain-containing proteins represent the largest class of potential histone demethylase proteins. The JmjC domain can catalyze the demethylation of mono-, di-, and tri-methyl lysine residues via an oxidative reaction that requires iron and α-ketoglutarate. Based on homology, both humans and mice contain at least 30 such proteins, which can be divided into 7 separate families. The JARID (Jumonji/AT-rich interactive domain-containing protein) family contains four members: JARID1A (also RBP2 and RBBP2), JARID1B (also PLU-1), JARID1C (also SMCX), and JARID1D (also SMCY). In addition to the JmJC domain, these proteins contain JmJN, BRIGHT, C5HC2 zinc-finger, and PHD domains, the latter of which binds to methylated histone H3 (Lys9). All four JARID proteins demethylate di- and tri-methyl histone H3 Lys4, JARID1B also demethylates mono-methyl histone H3 Lys4. JARID1A is a critical RB-interacting protein and is required for Polycomb-Repressive Complex 2 (PRC2)-mediated transcriptional repression during ES cell differentiation. A JARID1A-NUP98 gene fusion is associated with myeloid leukemia. JARID1B, which interacts with many proteins including c-Myc and HDAC4, may play a role in cell fate decisions by blocking terminal differentiation. JARID1B is overexpressed in many breast cancers and may act by repressing mμltiple tumor suppressor genes, including BRCA1 and HOXA5 . JARID1C has been found in a complex with HDAC1, HDAC2, G9a, and REST, which binds to and represses REST target genes in non-neuronal cells. JARID1C mutations are associated with X-linked mental retardation and epilepsy. JARID1D is uniquely localized to the Y chromosome, and functions as a tumor suppressor by repressing genes associated with cell invasiveness. JARID1D is frequently mutated in metastatic prostate tumors, and low JARID1D levels are associated with poor prognosis in prostate cancer patients.

Category: Primary Antibody

Reactivity: Human

Host: Mouse

Applications: WB, IF/ICC

Alternate Names: DXS1272E, JARID1C, SMCX, XE169, Lysine-specific demethylase 5C, Histone demethylase JARID1C, Jumonji/ARID domain-containing protein 1C, Protein SmcX, Protein Xe169

Clonality: Monoclonal

Conjugate: Unconjugated

Modification: Unmodification

Immunogen: Purified recombinant human KDM5C / Jarid1C / SMCX protein fragments expressed in E.coli

Dilution: WB (1/500 - 1/1000), IF/ICC (1/50 - 1/100)

Purification: The antibody was purified by immunogen affinity chromatography.

Specificity: Recognizes endogenous levels of KDM5C protein.

Molecular Weight: ~ 200 kDa

Pathway: Histone Lysine Methylation Pathway

Storage and Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

SwissProt: P41229

Product: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide, pH 7.3.

Research Use Only